Associate Professor, Neurology, Yale University School of Medicine
Neurology
Dr. Serena S. Spudich, MD
|
|
Give Review
Serena Spudich practices Neurology. He attended University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is one of the top medical schools in the US. University of California San Francisco School of Medicine is ranked 3 in research and 3 in primary care medicine Serena S. Spudich is a published physician. He published 47 publications, including: 'Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene.' He accepts Medicare.
Publications
- Phenotypic Correlates of HIV-1 Macrophage Tropism.
- Neuropathogenesis of HIV: From Initial Neuroinvasion to HIV-Associated Neurocognitive Disorder (HAND).
- Compartmentalized Replication of R5 T Cell-Tropic HIV-1 in the Central Nervous System Early in the Course of Infection.
- Cerebral white matter integrity during primary HIV infection.
- Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection.
- Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.
- CROI 2014: neurologic complications of HIV infection.
- Peripheral Neuropathy in Primary HIV Infection Associates with Systemic and CNS Immune Activation.
- HIV Neurology.
- Evolving Character of Chronic Central Nervous System HIV Infection.
- Longitudinal Characterization of Depression and Mood States Beginning in Primary HIV Infection.
- HIV and Neurocognitive Dysfunction.
- Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection.
- Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.
- Central Nervous System Viral Invasion and Inflammation During Acute HIV Infection.
- Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.
- Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy.
- Minocycline Fails to Modulate Cerebrospinal Fluid HIV Infection or Immune Activation in Chronic Untreated HIV-1 Infection: Results of a Pilot Study.
- Central nervous system complications of HIV infection.
- Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
- HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia.
- Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection.
- Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV.
- Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection.
- Neurologic complications of HIV infection: highlights from the 2013 Conference on Retroviruses and Opportunistic Infections.
- Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected Subjects.
- HIV-1 replication in the central nervous system occurs in two distinct cell types.
- Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral bur...
- HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.
- Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection.
- Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.
- Antiretroviral therapy and central nervous system HIV type 1 infection.
- Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.
- Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.
- Defining and evaluating HIV-related neurodegenerative Disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers.
- Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
- Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
- Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.
- Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.
- Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.
- Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated Dementia.
- Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.
- Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system Disease.
- Complete penetrance of Creutzfeldt-Jakob Disease in Libyan Jews carrying the E200K mutation in the prion protein gene.
- Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.
- Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation.
Schools
University of California At San Francisco
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Brain Aneurysm
- Cerebral Artery Thrombosis
- View All
Doctors Specialties
- Neurology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Pathway X Ind PPO Direct Access CT
- Blue Card PPO
- Great West Healthcare-Cigna PPO
- Connecticare HMO
- Connecticare POS
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Freedom Plan
- Oxford Liberty
- United Healthcare
Education
-
Massachusetts General Hospital -
University of Washington -
University of California San Francisco School of Medicine
Drug Facts
| NPI NUMBER | 1851345300 | |
| NPPES Provider LastName | SPUDICH | |
| NPPES Provider FirstName | SERENA | |
| NPPES Provider ZIPCode | 065103221 | |
| NPPES Provider State | CT | |
| Specialty Description | Neurology | |
| Total Claim Count | 15.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851345300 |
| Last Name Of The Provider | SPUDICH |
| First Name Of The Provider | SERENA |
| View All |
Similar Doctors
|
|
Dr. Lawrence N. Levenson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaime Grutzendler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kimberly R. Robeson-Gewuerz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Russell, MD |
|
|
Dr. Mark M. Landreneau, MD |
|
|
Dr. Reversa R. Mills, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diana A. Richardson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah E. Buckingham, MD |
|
|
Dr. Naila Makhani, MD |